Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00050635CT.gov STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diarrheal Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sandostatin (this asset) | Novartis Pharmaceuticals | Approved | B · 62 |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | University of Southern California | P3 | BB |
| Irinotecan | Roswell Park Cancer Institute | P3 | BB |
| Loperamide | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB |
| Sulfasalazine | Alliance for Clinical Trials in Oncology | P3 | BB |
| Crofelemer | Napo Pharmaceuticals, Inc. | P3 | BB |
| L-Ofloxacin | Children's Oncology Group | P3 | BB |
| Elsiglutide | Helsinn Healthcare SA | P2 | B |
| Colesevelam | Memorial Sloan Kettering Cancer Center | P2 | B |
+16 more in the Diarrheal Disease cohort
Other indications for Sandostatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prader-Willi Syndrome | — | P3 | B · 57 |
| Obesity Disorder | — | P4 | CCC · 55 |
| Neoplasm | — | P4 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-University of Southern CaliforniaBB
- IrinotecanRoswell Park Cancer InstituteBB
- LoperamideSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBB
- SulfasalazineAlliance for Clinical Trials in OncologyBB
- CrofelemerNapo Pharmaceuticals, Inc.BB
Citation
Floatz Terminal. Sandostatin in Diarrheal Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sandostatin-diarrheal-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →